Delivery Order SPE2DB20D3101-SPE2DB23FRYT3
- Not listed
- This federal contract award is for the delivery of Lidocaine 5% patches to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract, valued at $1,804.18, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and an ultimate completion date of May 1, 2024. The contract is not associated with any...
- This federal contract award is for the delivery of Lidocaine 5% patches to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for a Firm Fixed Price Delivery Order valued at $1,021.06. The contract has an ultimate completion date of August 21, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award is for the delivery of Lidocaine 5% Patches to the Defense Logistics Agency (DLA), a major procurement agency within the U.S. Department of Defense. The prime contractor, Amerisourcebergen Drug Corp, was awarded a Firm Fixed Price Delivery Order valued at $2,093.83 with a completion date of February 7, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award is for the delivery of Lidocaine 5% patches to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,852.85, is a firm fixed-price delivery order with a completion date of July 26, 2022. The contract was awarded on July 25, 2022, and does not have a set-aside designation, indicating...
- This federal contract award is for the delivery of Lidocaine 5% Patch 30s to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,348.34, is a delivery order with a firm fixed price. There is no set-aside designation, indicating open competition. Amerisourcebergen is the subsidiary of the parent company, Cencora, Inc., which does business as Amerisourcebergen....
- This federal contract award is for the delivery of Lidocaine 5% patches to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The contract, valued at $9,893.94, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also does business as...
- This federal contract award is for the delivery of Lidocaine 5% Patches to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price of $8,916.79 and an ultimate completion date of January 13, 2022. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a...
- This federal contract award is for the delivery of Lidocaine 5% Patch 30s to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract, valued at $20,567.02, was awarded to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of the parent company Cencora, Inc. This is a delivery order contract with a firm fixed price, and there is no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical...
- This federal contract award is for the delivery of Lidocaine 5% Patch 30S to the Defense Logistics Agency (DLA). The $6,436.63 fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., which serves as the primary vehicle for the company to supply a comprehensive range of...
- This federal contract award is for the delivery of Lidocaine 5% Patches to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price of $4,355.76 and an Ultimate Completion Date of May 22, 2023. The contract is not designated with any set-aside requirements, indicating open competition....
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FRYT3Delivery Order
This federal contract award is for the delivery of Lidocaine 5% patches to the Defense Logistics Agency (DLA). The $6,358.47 contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Firm Fixed Price Delivery Order with a completion date of September 25, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award is issued under that larger IDC, demonstrating Amerisourcebergen's capacity to efficiently meet the DLA's diverse and critical pharmaceutical needs. The contract does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 9/22/23 |